Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Merck
AstraZeneca
QuintilesIMS
Fuji
Accenture
Fish and Richardson
US Department of Justice
Citi

Generated: May 23, 2018

DrugPatentWatch Database Preview

Astellas Company Profile

« Back to Dashboard

Summary for Astellas
International Patents:366
US Patents:29
Tradenames:17
Ingredients:13
NDAs:31
Patent Litigation for Astellas: See patent lawsuits for Astellas

Drugs and US Patents for Astellas

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas MYCAMINE micafungin sodium INJECTABLE;IV (INFUSION) 021506-002 Mar 16, 2005 RX Yes Yes 6,107,458 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Astellas CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER ceftizoxime sodium INJECTABLE;INJECTION 050589-001 Oct 3, 1984 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Astellas CEFIZOX IN PLASTIC CONTAINER ceftizoxime sodium INJECTABLE;INJECTION 050589-004 Apr 13, 1995 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Astellas ASTAGRAF XL tacrolimus CAPSULE, EXTENDED RELEASE;ORAL 204096-003 Jul 19, 2013 RX Yes Yes 6,440,458 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Astellas

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astellas ADENOSCAN adenosine SOLUTION;IV (INFUSION) 020059-001 May 18, 1995 5,070,877 ➤ Try a Free Trial
Astellas MYCAMINE micafungin sodium INJECTABLE;IV (INFUSION) 021506-002 Mar 16, 2005 6,265,536 ➤ Try a Free Trial
Astellas AMBISOME amphotericin b INJECTABLE, LIPOSOMAL;INJECTION 050740-001 Aug 11, 1997 5,965,156 ➤ Try a Free Trial
Astellas CYCLOCORT amcinonide CREAM;TOPICAL 018116-002 Approved Prior to Jan 1, 1982 4,158,055 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ASTELLAS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 3 mg/mL, 20 mL and 30 mL vials ➤ Subscribe 2005-04-18
➤ Subscribe Injection 0.08 mg/mL, 5 mL vial ➤ Subscribe 2012-04-10
➤ Subscribe Extended-release Capsules 0.5 mg, 1 mg, and 5 mg ➤ Subscribe 2013-11-15
➤ Subscribe Capsules 40 mg ➤ Subscribe 2016-08-31
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2009-04-08
➤ Subscribe Injection 3 mg/mL, 20 mL and 30 mL vials ➤ Subscribe 2005-04-16
➤ Subscribe For Injection 50 mg/vial and 100 mg/vial ➤ Subscribe 2014-06-16

Non-Orange Book US Patents for Astellas

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,671,192 Process for preparing an A.sub.2A-adenosine receptor agonist and its polymorphs ➤ Try a Free Trial
7,112,565 Stabilized pharmaceutical composition in lyophilized form ➤ Try a Free Trial
8,278,435 N-pyrazole A2A receptor agonists ➤ Try a Free Trial
6,174,896 Quinuclidine derivatives and medicinal composition thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Astellas Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
15/073 Ireland ➤ Try a Free Trial PRODUCT NAME: ISAVUCONAZOLE AS ISAVUCONAZONIUM SULFATE OR AS ISAVUCONAZONIUM SALT WITH ANY OTHER PHARMACEUTICALLY ACCEPTABLE ANION, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE; REGISTRATION NO/DATE: EU/1/15/1036 20151015
C004/2011 Ireland ➤ Try a Free Trial SPC004/2011: 20110719, EXPIRES: 20250620
2013 00065 Denmark ➤ Try a Free Trial PRODUCT NAME: ENZALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/846 20130625
0352 Netherlands ➤ Try a Free Trial 300352, 20150929, EXPIRES: 20200928
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Argus Health
Daiichi Sankyo
Dow
Cerilliant
Mallinckrodt
Medtronic
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.